Biogen: redeployment of resources in Alzheimer’s

Biogen: FDA approval for Alzheimer’s disease

Biogen: Jefferies maintains its rating on the title

Biogen revamps its Parkinson’s disease program

Biogen: English marketing application for lecanemab

Biogen idec: New data on multiple sclerosis

Biogen idec: FDA accepts application for LEQEMBI